ARIIS

What ARIIS does

ARIIS (Alliance pour la Recherche et l'Innovation des Industries de Santé) is a French non-profit association (association loi 1901) founded around 2010 and headquartered at PariSanté Campus in Paris (SIREN 407666544). Its stated purpose is to accelerate health innovation by acting as a strategic trusted third party that catalyzes interactions and co-construction projects between private health industry players and public research actors in France. ARIIS serves four horizontal segments: large healthcare companies (its primary paying members), public research institutions (INSERM, universities, hospitals), health startups, and government/public institutions involved in health research policy.

The organization does not sell a technology product. Instead, its portfolio consists of research programs (AI & Cancer, AI & Health Programme, AI & Rare Diseases, AI & Care Pathways, DATA GOV LAB, New Methodologies for Clinical Trials), recurring event programs (Cohort Innovation Day international meetings, HYBRID events, Learning Expeditions, webinars), and publications — most notably a 2026 position paper on Synthetic Control Arms co-authored with Sanofi and SILICA. Distribution is conducted through direct membership engagement and events; pricing is not publicly disclosed, consistent with a membership-funded non-profit model. Operationally, ARIIS is lean, with 1-10 employees, a newly appointed President (Nathalie Varoqueaux MD PhD), and a vice president (Tiberius Pircalabu). Strategic communications run through LinkedIn, a YouTube channel (@ariisreplay), the ariis.fr website, and an email newsletter, alongside formal annual activity reports and position papers.

Name

ARIIS

Legal name

Alliance pour la Recherche et l'Innovation des Industries de Santé (ARIIS)

Website

https://ariis.fr

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

ARIIS is a French non-profit alliance coordinating public-private health research collaboration among large pharma companies, public research institutions, startups, and government bodies, via research programs, events, and policy publications.

Ownership category

akta.pro rank

Product category

Health Research Alliance Services

NAICS

Business Associations (813910)

SIC

Services-Membership Organizations (8600)

akta.pro industry

PRIMARYBPADANAJ

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation

Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation

SECONDARYHLAJAKAN

Global Health Research, Evidence & Technical Assistance Organizations

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)

Keywords

• Health research alliance
• Public-private partnerships
• Life sciences innovation
• Clinical trial collaboration
• Healthcare industry coordination

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Distribution channels1 record

Marketing channels4 records

Core offering

ARIIS is a French alliance organization (loi 1901) that coordinates public-private partnerships in health research between large healthcare companies, public research institutions, health startups, and government bodies. It delivers research programs focused on AI in healthcare, organizes international events such as Cohort Innovation Day and Learning Expeditions, publishes position papers with industry partners, and facilitates B2B meetings and working groups to accelerate health innovation in France.

Product overview

ARIIS (Alliance pour la Recherche et l'Innovation des Industries de Santé) is not a technology product company but rather a strategic alliance organization dedicated to accelerating health innovation in France. Rather than offering a unified software platform, ARIIS operates as a catalyst for public-private collaboration, coordinating research programs, events, and working groups. Their portfolio includes research initiatives focused on AI applications in healthcare (AI & Cancer, AI & Health Programme, AI & Rare Diseases, AI & Care Pathways), event programs (Cohort Innovation Day, HYBRID, Learning Expeditions, Webinars), publications (Position Paper on Synthetic Control Arms with SILICA and SANOFI), and methodology development projects (New Methodologies for Clinical Trials, DATA GOV LAB). The organization serves as a trusted intermediary between public research institutions and private health industry players, focusing on federation, accompaniment, and co-construction of health innovation initiatives.

Differentiator

Problem solved

Functional benefit

Products and services

• AI & Cancer Project

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered core and major.

• INSERMcoreStrategic or Co-development PartnerINSERM (Institut national de la santé et de la recherche médicale) is the French National Institute of Health and Medical Research. ARIIS collaborates with INSERM as part of its mission to foster public-private partnerships in health research. The partnership appears in logo sections of ARIIS events and publications.
• AviesancoreStrategic or Co-development PartnerAviesan is the French Alliance for Life Sciences and Health. Appears as a partner in ARIIS publications and events. The alliance coordinates major actors in French health research.
• MEDECENcoreStrategic or Co-development PartnerMEDECEN appears as a partner in ARIIS event materials. The cluster promotes innovation in health technologies and medicine in the Paris region.
• SanofimajorStrategic or Co-development PartnerSanofi collaborated with ARIIS and SILICA on a position paper regarding 'Synthetic Control Arms and Clinical Trials: Building Tomorrow's Framework to Accelerate Access to Therapeutic Innovations'. Published June 2026.
• SILICAmajorStrategic or Co-development PartnerSILICA collaborated with ARIIS and Sanofi on the position paper regarding synthetic control arms and clinical trials framework development.
• Haute Autorité de SantécoreStrategic or Co-development PartnerFrench Health Authority (HAS) with whom ARIIS shares positions on scientific robustness and innovation confidence in health. Mentioned in July 2026 news regarding HAS Director Jean Lessi's position on production methods of evidence.
• Direction Générale de la Recherche, de l'Innovation et du Numérique en Santé (DGRINS)coreStrategic or Co-development PartnerNewly created French government body for research, innovation and digital health. ARIIS reported on July 10, 2026 about official texts creating DGRINS as a new step for digital transformation and health innovation in France.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• EuropaBio: European biotech industry association. Comparable to ARIIS in representing health innovation stakeholders, but at the European level with broader scope than ARIIS's national coordination role.
• MedTech Europe: European trade association for the medical technology industry including diagnostics and digital health. Comparable to ARIIS as a broader health industry alliance with policy advocacy and member coordination, but operating at the EU level.
• EFPIA (European Federation of Pharmaceutical Industries and Associations): Pan-European pharma industry association representing major pharmaceutical companies and national associations (including France). Comparable to ARIIS as a broader incumbent in health industry coordination with policy advocacy, operating at the EU rather than national level.

Direct peers

• France Biotech: French association of health tech and biotech startups and their investors. Directly comparable to ARIIS as a French health innovation alliance, although focused more on the startup/innovation segment that ARIIS also serves.
• SNITEM (Syndicat National de l'Industrie des Technologies Médicales): French medical devices industry trade association. Comparable to ARIIS as a national alliance coordinating industry actors in the French health ecosystem and engaging with regulators and government bodies.
• LEEM (Les Entreprises du Médicament): French pharmaceutical industry association representing medicine-producing companies in France. Highly comparable to ARIIS as a national health industry alliance that convenes pharma companies and engages with French health authorities and policy.

Regional players

• BIO (Biotechnology Innovation Organization): Largest US biotechnology trade association. Comparable to ARIIS as a major health innovation industry alliance with policy advocacy, events, and working groups, but operating primarily in the United States.
• French Healthcare: French public initiative promoting French healthcare expertise internationally. Comparable to ARIIS as a French health ecosystem organization that connects industry, public institutions, and policy actors, with a more international/export-promotion mandate.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• YouTubeyoutube.com/@ariisreplay
• LinkedInlinkedin.com/company/ariis-health-industry-alliance-for-research-and-innovation

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARIIS